二甲双胍在恶性肿瘤治疗中的研究进展

段雪玉; 廖彬彬; 李蕾; 张鼎才; 陈瑞祥; 刘晓波

doi:10.6039/j.issn.1001-0408.2024.15.20

您当前的位置：

首页 >

文章列表页 >

二甲双胍在恶性肿瘤治疗中的研究进展

综述 | 更新时间：2024-08-11

- 二甲双胍在恶性肿瘤治疗中的研究进展
- Research progress on metformin in the treatment for malignant tumors
- 中国药房 2024年35卷第15期页码：1915-1922
- 作者机构：
  
  1.大理大学药学院，云南大理;671003
  2.中国人民解放军联勤保障部队第926医院药剂科，云南开远　661600
  3.云南省第三人民医院药剂科，昆明　650011
  4.云南省昆虫生物医药研发重点实验室（大理大学），云南大理　671003
- 作者简介：
  
  硕士。研究方向：临床药学。E-mail：2063776349@ qq.com
  教授，硕士生导师，硕士。研究方向：中药药理。 E-mail：yndlxb@126.com
- 基金信息：
  
  云南省科技厅科技计划项目（No.202101BA070001-
- DOI：10.6039/j.issn.1001-0408.2024.15.20
  中图分类号： R977.1+5;R979.1
- 纸质出版日期：2024-08-15，
  
  收稿日期：2023-11-17，
  
  修回日期：2024-06-14，
- 稿件说明：
扫描看全文
段雪玉,廖彬彬,李蕾等.二甲双胍在恶性肿瘤治疗中的研究进展 ^Δ[J].中国药房,2024,35(15):1915-1922.

DUAN Xueyu,LIAO Binbin,LI Lei,et al.Research progress on metformin in the treatment for malignant tumors[J].ZHONGGUO YAOFANG,2024,35(15):1915-1922.
段雪玉,廖彬彬,李蕾等.二甲双胍在恶性肿瘤治疗中的研究进展 ^Δ[J].中国药房,2024,35(15):1915-1922. DOI： 10.6039/j.issn.1001-0408.2024.15.20.

DUAN Xueyu,LIAO Binbin,LI Lei,et al.Research progress on metformin in the treatment for malignant tumors[J].ZHONGGUO YAOFANG,2024,35(15):1915-1922. DOI： 10.6039/j.issn.1001-0408.2024.15.20.

摘要

近年来二甲双胍潜在的抗肿瘤效果在肿瘤治疗领域引起了广泛关注。本文综述了二甲双胍在恶性肿瘤治疗中的研究进展，发现其在消化系统恶性肿瘤（胆道癌、胃癌、食管癌、结直肠癌、胰腺癌、肝癌）、生殖系统恶性肿瘤（前列腺癌、卵巢癌、乳腺癌、宫颈癌）、非小细胞肺癌、肾细胞癌和黑色素瘤等治疗中显示出应用潜力。二甲双胍可抑制肿瘤细胞的增殖并延长患者的总生存期，其作用机制包括但不限于抑制线粒体复合物Ⅰ活性、激活腺苷一磷酸活化蛋白激酶/p53信号通路、阻滞细胞周期等。二甲双胍与化疗药物的联合使用显示出了减毒增效的潜力，其能增强胆道癌、卵巢癌和黑色素瘤细胞对化疗药物的敏感性，改善胃癌和结直肠癌细胞对化疗药物的耐药性，并减少乳腺癌患者在化疗过程中的毒性反应。二甲双胍还被用作免疫调节剂，应用于食管癌、结直肠癌、宫颈癌、非小细胞肺癌以及黑色素瘤患者的免疫治疗。

Abstract

In recent years， the potential anti-tumor effects of metformin have attracted widespread attention in the field of cancer treatment. This article summarizes the research progress of metformin in the treatment of malignant tumors，finding its potential application in the treatment of malignant tumors in the digestive system （biliary tract cancer，gastric cancer，esophagus cancer，colorectal cancer，pancreatic cancer，liver cancer） and reproductive system （prostate cancer，ovarian cancer，breast cancer，cervical cancer），non-small cell lung cancer，renal cell carcinoma，and melanoma. Metformin can inhibit the proliferation of tumor cells and extend the overall survival of patients. Its mechanisms of action include，but are not limited to，inhibiting the activity of mitochondrial complex Ⅰ，activating adenosine monophosphate-activated protein kinase/p53 signaling pathway，and blocking the cell cycle. Additionally，the combined use of metformin with chemotherapy drugs has shown potential for reducing toxicity and enhancing efficacy. It can enhance the sensitivity of biliary tract cancer，ovarian cancer，and melanoma cells to chemotherapy drugs，improve the drug resistance of gastric and colorectal cancer cells to chemotherapy，and reduce the toxic reactions of breast cancer patients during chemotherapy. Metformin is also used as an immunomodulator，applied in the immunotherapy of patients with esophagus cancer，colorectal cancer，cervical cancer，non-small cell lung cancer，and melanoma.

关键词

二甲双胍恶性肿瘤作用机制临床应用

Keywords

malignant tumorsmechanism of actionclinical application

references

SIEGEL R，MILLER K，WAGLE N S，et al. Cancer sta- tistics，2023[J]. CA Cancer J Clin，2023，73（1）：17-48.

CASADEI-GARDINI A，FILIPPI R，RIMINI M，et al. Effects of metformin and vitamin D on clinical outcome in cholangiocarcinoma patients[J]. Oncology，2021，99（5）：292-299.

TSENG C H. Metformin and biliary tract cancer in patients with type 2 diabetes[J]. Front Oncol，2020，10：587666.

LING S B，XIE H Y，YANG F，et al. Metformin poten- tiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma：roles of p38 MAPK，ERK3，and mTORC1[J]. J Hematol Oncol，2017，10（1）：59.

CHEN J H，JIN H W，ZHOU H，et al. Effects of metformin on risk and prognosis of biliary tract cancer：a syste- matic review and meta-analysis[J]. Medicina，2023，59（2）：298.

THRIFT A P，EL-SERAG H B. Burden of gastric cancer[J]. Clin Gastroenterol Hepatol，2020，18（3）：534-542.

ZHENG J J，SANTONI G，XIE S H，et al. Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study[J]. Br J Cancer，2021，125（2）：277-283.

LU H B，HAN X W，REN J Z，et al. Metformin attenuates synergic effect of diabetes mellitus and Helicobacter pylori infection on gastric cancer cells proliferation by suppressing PTEN expression[J]. J Cell Mol Med，2021，25（10）：4534-4542.

HUANG F，XIANG Y，LI T，et al. Metformin and miR-365 synergistically promote the apoptosis of gastric cancer cells via miR-365-PTEN-AMPK axis[J]. Pathol Res Pract，2022，230：153740.

KAO H W，TSAI K W，LIN W C. Synergistic effect of metformin and lansoprazole against gastric cancer through growth inhibition[J]. Int J Med Sci，2023，20（6）：717-724.

WANG F，DING X F，WANG T，et al. Metformin inhi- bited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin[J]. PLoS One，2017，12（4）：e0174276.

WANG Q L，SANTONI G，LAGERGREN J. Diabetes，metformin use，and survival in esophageal cancer：a population-based cohort study[J]. JNCI Cancer Spectr，2023，7（4）：pkad043.

VERDURA S，CUYÀS E，MARTIN-CASTILLO B，et al. Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy[J]. Oncoimmunology，2019，8（10）：e1633235.

WANG S H，LIN Y S，XIONG X，et al. Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer：results of a phase Ⅱ clinical trial[J]. Clin Cancer Res，2020，26（18）：4921-4932.

LU Y，XIN D，GUAN L L，et al. Metformin downregulates PD-L1 expression in esophageal squamous cell carcinoma by inhibiting IL-6 signaling pathway[J]. Front Oncol，2021，11：762523.

PENG J W，JING X B，WU J L，et al. Metformin’s effects on apoptosis of esophageal carcinoma cells and normal esophageal epithelial cells：an in vitro comparative study[J]. Biomed Res Int，2020，2020：1068671.

HONG J，MAACHA S，PIDKOVKA N，et al. AXL promotes metformin-induced apoptosis through mediation of autophagy by activating ROS-AMPK-ULK1 signaling in human esophageal adenocarcinoma[J]. Front Oncol，2022，12：903874.

BULLMAN S，PEDAMALLU C S，SICINSKA E，et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer[J]. Science，2017，358（6369）：1443-1448.

HONG X L，YU T C，HUANG X W，et al. Metformin abrogates Fusobacterium nucleatum-induced chemoresistance in colorectal cancer by inhibiting miR-361-5p/sonic Hedgehog signaling-regulated stemness[J]. Br J Cancer，2023，128（2）：363-374.

NG C W，JIANG A A，TOH E M S，et al. Metformin and colorectal cancer：a systematic review，meta-analysis and meta-regression[J]. Int J Colorectal Dis，2020，35（8）：1501-1512.

HUANG X W，SUN T T，WANG J L，et al. Metformin reprograms tryptophan metabolism to stimulate CD8+ T-cell function in colorectal cancer[J]. Cancer Res，2023，83（14）：2358-2371.

SHI Y Q，ZHOU X C，DU P，et al. Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes：a systematic review and meta-analysis[J]. Medicine，2020，99（37）：e21687.

SCARTON L，JO A，XIE Z G，et al. Examining the relationship between metformin dose and cancer survival：a SEER-medicare analysis[J]. PLoS One，2022，17（10）：e0275681.

REN D Y，QIN G D，ZHAO J Y，et al. Metformin ac- tivates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer[J]. Am J Cancer Res，2020，10（9）：2851-2864.

YUAN B，MA J C，WANG J，et al. The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy[J]. Front Endocrinol，2022，13：1060768.

SUN R J，ZHAI R R，MA C L，et al. Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway[J]. Cancer Med，2020，9（3）：1141-1151.

RICHARDS K A，LIOU J I，CRYNS V L，et al. Metformin use is associated with improved survival for patients with advanced prostate cancer on androgen deprivation therapy[J]. J Urol，2018，200（6）：1256-1263.

FREEDMAN L S，AGAY N，FARMER R，et al. Metformin treatment among men with diabetes and the risk of prostate cancer：a population-based historical cohort study[J]. Am J Epidemiol，2022，191（4）：626-635.

YE J H，CAI S H，FENG Y F，et al. Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer[J]. Signal Transduct Target Ther，2023，8（1）：303.

BROWN J R，CHAN D K，SHANK J J，et al. Phase Ⅱ clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer[J]. JCI Insight，2020，5（11）：e133247.

DANG J H，JIN Z J，LIU X J，et al. Metformin in combination with cisplatin inhibits cell viability and induces apoptosis of human ovarian cancer cells by inactivating ERK1/2[J]. Oncol Lett，2017，14（6）：7557-7564.

SINGH S K，APATA T，SINGH S，et al. Clinical implication of metformin in relation to diabetes mellitus and ovarian cancer[J]. Biomedicines，2021，9（8）：1020.

TANG G H，SATKUNAM M，POND G R，et al. Asso- ciation of metformin with breast cancer incidence and mortality in patients with type Ⅱ diabetes：a GRADE-assessed systematic review and meta-analysis[J]. Cancer Epidemiol Biomarkers Prev，2018，27（6）：627-635.

WANG Q D，MA X F，LONG J P，et al. Metformin and survival of women with breast cancer：a meta-analysis of randomized controlled trials[J]. J Clin Pharm Ther，2022，47（3）：263-269.

RAHMANI J，MANZARI N，THOMPSON J，et al. The effect of metformin on biomarkers associated with breast cancer outcomes：a systematic review，meta-analysis，and dose-response of randomized clinical trials[J]. Clin Transl Oncol，2020，22（1）：37-49.

SERAGELDIN M A，KASSEM A B，EL-KERM Y，et al. The effect of metformin on chemotherapy-induced toxicities in non-diabetic breast cancer patients：a randomised controlled study[J]. Drug Saf，2023，46（6）：587-599.

YANG J J，ZHOU Y L，XIE S D，et al. Metformin induces ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer[J]. J Exp Clin Cancer Res，2021，40（1）：206.

KIM H M，KANG M J，SONG S O. Metformin and cervical cancer risk in patients with newly diagnosed type 2 diabetes：a population-based study in Korea[J]. Endocrinol Metab （Seoul），2022，37（6）：929-937.

CHEN Y H，YANG S F，YANG C K，et al. Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells[J]. Mol Med Rep，2021，23（1）：88.

XIA C L，LIU C，HE Z H，et al. Metformin inhibits cervical cancer cell proliferation by modulating PI3K/Akt-induced major histocompatibility complex class Ⅰ-related chain A gene expression[J]. J Exp Clin Cancer Res，2020，39（1）：127.

LU T，LI M，ZHAO M N，et al. Metformin inhibits human non-small cell lung cancer by regulating AMPK-CEBPB-PDL1 signaling pathway[J]. Cancer Immunol Immunother，2022，71（7）：1733-1746.

ZHU Z L，JIANG T，SUO H R，et al. Metformin poten- tiates the effects of anlotinib in NSCLC via AMPK/mTOR and ROS-mediated signaling pathways[J]. Front Pharmacol，2021，12：712181.

ZHANG Q M，ZHENG J，WANG W，et al. The anticancer effect of metformin combined with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients with or without type 2 diabetes mellitus：a systematic review and meta-analysis[J]. Oncol Ther，2022，10（2）：363-375.

TSAKIRIDIS T，POND G R，WRIGHT J，et al. Metformin in combination with chemoradiotherapy in locally advanced non-small cell lung cancer：the OCOG-ALMERA randomized clinical trial[J]. JAMA Oncol，2021，7（9）：1333-1341.

SKINNER H，HU C，TSAKIRIDIS T，et al. Addition of metformin to concurrent chemoradiation in patients with locally advanced non-small cell lung cancer：the NRG-LU001 phase 2 randomized clinical trial[J]. JAMA Oncol，2021，7（9）：1324-1332.

LEE Y，JOO J，LEE Y J，et al. Randomized phase Ⅱ study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer[J]. Lung Cancer，2021，151：8-15.

WANG Z G，LU C H，ZHANG K J，et al. Metformin combining PD-1 inhibitor enhanced anti-tumor efficacy in STK11 mutant lung cancer through AXIN-1-dependent inhibition of STING ubiquitination[J]. Front Mol Biosci，2022，9：780200.

ZHAO Y W，LUO Q M，MO J R，et al. Metformin in combination with JS-K inhibits growth of renal cell carcinoma cells via reactive oxygen species activation and inducing DNA breaks[J]. J Cancer，2020，11（13）：3701-3712.

HAMIEH L，MCKAY R R，LIN X，et al. Effect of metformin use on survival outcomes in patients with metastatic renal cell carcinoma[J]. Clin Genitourin Cancer，2017，15（2）：221-229.

LIU M H，ZHANG Z，WANG H，et al. Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2[J]. Int J Biol Sci，2019，15（3）：617-627.

GE L，WU Y G，WAN M，et al. Metformin increases sensitivity of melanoma cells to cisplatin by blocking exosomal-mediated miR-34a secretion[J]. J Oncol，2021，2021：5525231.

MONTAUDIÉ H，CEREZO M，BAHADORAN P，et al. Metformin monotherapy in melanoma：a pilot，open-label，prospective，and multicentric study indicates no benefit[J]. Pigment Cell Melanoma Res，2017，30（3）：378-380.

AFZAL M Z，MERCADO R R，SHIRAI K. Efficacy of metformin in combination with immune checkpoint inhibitors （anti-PD-1/anti-CTLA-4） in metastatic malignant melanoma[J]. J Immunother Cancer，2018，6（1）：64.

CICCARESE C，IACOVELLI R，BUTI S，et al. Concurrent nivolumab and metformin in diabetic cancer patients：is it safe and more active?[J]. Anticancer Res，2022，42（3）：1487-1493.

ZHUANG A，CHAI P W，WANG S Y，et al. Metformin promotes histone deacetylation of optineurin and suppresses tumour growth through autophagy inhibition in ocular melanoma[J]. Clin Transl Med，2022，12（1）：e660.

ABDELMONEIM M，ABOALELA M A，NAOE Y，et al. The impact of metformin on tumor-infiltrated immune cells：preclinical and clinical studies[J]. Int J Mol Sci，2023，24（17）：13353.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

艾拉莫德应用于结缔组织病的作用机制与临床研究进展

五指毛桃及其制剂在临床中的应用

土大黄的药理作用及临床应用研究进展

碳酸锂的临床应用及其毒性研究进展

米非司酮在妇产科的应用研究进展